Retatrutide, a Triple-Agonist GLP-1 in Southlake, TX
Retatrutide is a weight loss medication that acts on three receptors. Dr. Mikki weighs it against the approved options and confirms candidacy at your consultation.
- Google 4.8★
- Yelp 5.0★
What retatrutide is
Retatrutide is an investigational triple-agonist peptide. It acts on the GLP-1, GIP, and glucagon receptors, where semaglutide acts on one and tirzepatide on two. It is newer than both and remains in clinical trials, so Dr. Mikki discusses it conservatively and weighs it against the approved medications before recommending anything.
How the three receptors work
GLP-1, GIP and glucagon are three signals your body already uses to manage appetite, insulin and energy. Retatrutide acts on all three at once, which is the mechanical difference between it and every GLP-1 medication now on the market.
Where retatrutide stands today
This is the first thing to know about retatrutide, so it is not buried further down the page. It is an investigational medication under active study, and that status shapes every conversation Dr. Mikki has about it.
Investigational
Not FDA-approved
Retatrutide is an investigational peptide. It has not been approved by the FDA for weight management or for anything else, and no page on this site should be read as saying otherwise.
Phase III
Where the research stands
Retatrutide, developed and patented by Eli Lilly, is currently in Phase III trials. It is not a compoundable peptide, so a trial arranged through a research hospital or ClinicalTrials.gov is the only route to it, and that is not something this practice provides.
Approved options
What is available now
Semaglutide and liraglutide are FDA-approved GLP-1 medications for weight loss and blood-sugar control. Where retatrutide is not an option, these are the ones Dr. Mikki works with.
How Dr. Mikki approaches it
Where retatrutide sits
Retatrutide is the third GLP-1 option Medrein discusses within medical weight loss, alongside the more established tirzepatide and semaglutide. Because it is emerging, Dr. Mikki treats it as a considered option rather than a first step. She reviews your history, explains the trade-offs, and decides candidacy with you.
| Feature | Retatrutide | Tirzepatide | Semaglutide |
|---|---|---|---|
| Acts on the GLP-1 receptor | Included | Included | Included |
| Acts on the GIP receptor | Included | Included | Not included |
| Acts on the glucagon receptor | Included | Not included | Not included |
| Established, longer track record | Not included | Included | Included |
What the research looks at beyond weight
Every item below is a finding reported in the clinical studies retatrutide is being evaluated in. They are reasons the molecule is of interest to researchers, not outcomes anyone can promise you, and individual results vary.
What a program looks like
Consultation and a full check-up
Your visit starts with a full review of your health history, your current medications, what you have already tried and what you are aiming for. Dr. Mikki evaluates each patient individually rather than against a protocol.
Where retatrutide sits against the approved options
Before anything is prescribed, she walks through semaglutide and tirzepatide, what each one is approved for, and why she considers retatrutide mainly for patients who have not reached their goals on those.
Baseline labs
Bloodwork sets the starting line and catches the metabolic problems that make weight loss harder when they go untreated: blood sugar, insulin resistance and the wider panel Dr. Mikki reads alongside them.
A physician-set protocol
If a GLP-1 medication is prescribed, it is a weekly subcutaneous injection, started low and adjusted gradually against your response and your tolerance.
Follow-up and adjustment
She monitors all patients closely and adjusts protocols as needed. Nutrition and activity run alongside the medication, because the studies she cites show medicine plus lifestyle change outperforming medicine alone.
Safety and side effects
How the practice handles it
- Dr. Mikki, a board-certified physician, reviews your history and your current medications before anything is prescribed.
- Candidacy is evaluated individually. Her starting position is the medications with a longer track record, not the newest one.
- Retatrutide itself is not dispensed by this practice. Any approved GLP-1 medication Dr. Mikki does prescribe is sourced through reputable compounding pharmacies rather than shipped to you unseen.
- You are monitored closely and the protocol is adjusted to how you have actually responded.
- In the clinical trials her blog cites, there were no severe adverse events reported.
What to weigh honestly
- Retatrutide is investigational. It is not FDA-approved, and its long-term profile is still being established in Phase III trials.
- Nausea, vomiting or diarrhea: the common ones, most often when first starting.
- Decreased appetite, sometimes beyond what is useful, and other digestive changes.
- Side effects typically diminish as the body adjusts, but tell Dr. Mikki rather than pushing through them.
- Heart rate can rise on this class of medication. Say so if you feel your heart beating faster than normal.
Who retatrutide is considered for
Dr. Mikki confirms candidacy at consultation against your history and your labs, and will say when a different option fits better: semaglutide where a single approved pathway is the right starting point, tirzepatide where a second receptor and an approval for chronic weight management matter, or the wider medical weight loss program where medication is only one part of the answer.
A good fit
- Adults with a BMI of 30 or higher.
- A BMI of 27 or higher alongside a weight-related health condition.
- Patients who have not reached their goals on semaglutide or tirzepatide, or who have plateaued on another GLP-1 medication.
- People seeking significant, sustainable weight loss under medical supervision rather than on their own.
- Anyone willing to have a full check-up, baseline labs and close follow-up as part of the plan.
Not the right treatment
- Anyone who wants an FDA-approved medication. Retatrutide is not one; semaglutide and liraglutide are the approved alternatives.
- Anyone who has not yet tried the established options. Dr. Mikki weighs those first.
- A BMI below those thresholds with no weight-related condition.
- Anyone who cannot commit to monitoring, including keeping an eye on heart rate.
- Anyone expecting the medication to do the work on its own. Her own sources put lifestyle change alongside it, not after it.
Before you book, three things worth knowing
Retatrutide is investigational and not FDA-approved, so the honest conversation starts with what is approved and available today. The weight-loss figures you have read are trial figures measured under trial conditions, not a forecast for you. And candidacy is a physician's call made at your visit, after a full check-up and baseline labs. Results vary from patient to patient.
What to expect, and how long it takes
These are the only windows the published material describes, and nothing beyond them is implied here. The dose is raised gradually, so the change is gradual: there are no shortcuts.
The first weeks
Appetite and the settling-in period
Reduced appetite is the change most patients report first. Nausea and other digestive effects are also most common at the start and typically diminish as the body adjusts.
Through titration
Gradual by design
The dose is raised gradually against your response and your tolerance, so the change is gradual too. There are no shortcuts, and nothing about this schedule is meant to be fast.
48 weeks
What the trials measured
In early clinical trials, some participants lost up to 24% of body weight over 48 weeks. That is a trial figure, not a promise, and it was measured under trial conditions rather than at this practice.
Your own case
What actually decides it
Individual results depend on dosing, lifestyle factors and treatment duration, and results vary from patient to patient. Dr. Mikki sets a realistic timeline for your case at the first visit.
What patients say about the conversation
These reflect common patient sentiment rather than verbatim quotes, and individual results vary.
I asked about retatrutide because I had read about it. Dr. Mikki did not just hand it over. She walked through where it sits against the medications with a longer track record and was honest that it is still in trials. Results may vary, but I left understanding the trade-offs instead of a sales pitch.
She explained why she starts with the established options first. No pressure, just the reasoning.
Frequently asked questions
What is retatrutide?
Retatrutide is an investigational triple-agonist peptide. It acts on three receptors, GLP-1, GIP, and glucagon, rather than the one or two its predecessors act on. It is newer than semaglutide and tirzepatide and remains in clinical trials, so Dr. Mikki discusses it conservatively.
Is retatrutide FDA-approved?
No. Retatrutide is investigational and is currently in Phase III trials, which means it must still be approved by regulatory agencies before it becomes generally available. Semaglutide and liraglutide are FDA-approved GLP-1 medications that Dr. Mikki works with in the meantime, and enrolling in a retatrutide trial is arranged through a research hospital or ClinicalTrials.gov rather than through this practice.
How is retatrutide different from semaglutide and tirzepatide?
Semaglutide acts on one receptor, GLP-1. Tirzepatide acts on two, GLP-1 and GIP. Retatrutide adds a third, glucagon, the receptor that signals the body to use stored fat for energy, so it raises the energy you burn instead of only lowering what you eat. More receptors does not automatically mean a better fit for you. Dr. Mikki weighs the more established options first and confirms candidacy at your consultation.
Who is a candidate for retatrutide therapy?
Dr. Mikki considers retatrutide for adults with a BMI of 30 or higher, or a BMI of 27 or higher alongside a weight-related health condition. Patients who have plateaued on another GLP-1 medication may also be candidates. She evaluates each patient individually, and candidacy is decided at your consultation rather than before it.
What results have clinical trials shown?
Clinical trials have shown retatrutide may produce greater weight loss than single or dual-agonist medications, with some participants losing up to 24% of body weight in studies over 48 weeks. That is a trial figure rather than an expectation. Individual results depend on dosing, lifestyle factors and treatment duration, and results vary from patient to patient.
What are the side effects of retatrutide?
Common side effects are similar to other GLP-1 medications and may include mild nausea, vomiting, diarrhea, decreased appetite and other digestive changes, most often when first starting. These typically diminish as your body adjusts. Heart rate can also rise on this class of medication, so tell Dr. Mikki if you feel your heart beating faster than normal. She monitors all patients closely and adjusts protocols as needed.
Are there benefits beyond weight loss?
The studies report improved blood sugar control and insulin sensitivity, reduced cardiovascular risk factors, potential improvements in fatty liver disease, decreased inflammation markers and enhanced metabolic flexibility. These are research findings rather than promises, and they are of most interest where metabolic syndrome or prediabetes sits alongside the weight.
How would retatrutide be taken and monitored?
In the trials, it is a weekly subcutaneous injection, started low and adjusted gradually based on response and tolerance. It is not something this practice can supply: retatrutide is patented by Eli Lilly and remains in Phase III, so it is not available through a pharmacy. For the approved GLP-1 medications Dr. Mikki does prescribe, she sources them through reputable compounding pharmacies, monitors your response, and manages side effects rather than telling you to push through them. Nutrition and activity run alongside the medication.
How do I get started?
Book a consultation online or call (214) 702-5225. Dr. Mikki reviews your history, explains where retatrutide sits among the GLP-1 options and what its investigational status means, and confirms whether a medication is appropriate for you.
Ask where retatrutide fits for you
Dr. Mikki reviews your history, explains the GLP-1 options, and confirms candidacy before anything is prescribed.
4.8★ from 128 verified Google reviews